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Many cancer therapeutics target DNA and exert cytotoxicity
through the induction of DNA damage and inhibition of transcrip-
tion. We report that a DNA minor groove binding hairpin pyrrole-
imidazole (Py-Im) polyamide interferes with RNA polymerase II
(RNAP2) activity in cell culture. Polyamide treatment activates p53
signaling in LNCaP prostate cancer cells without detectable DNA
damage. Genome-wide mapping of RNAP2 binding shows re-
duction of occupancy, preferentially at transcription start sites,
but occupancy at enhancer sites is unchanged. Polyamide treat-
ment results in a time- and dose-dependent depletion of the
RNAP2 large subunit RPB1 that is preventable with proteasome
inhibition. This polyamide demonstrates antitumor activity in
a prostate tumor xenograft model with limited host toxicity.
minor groove binder | small molecule transcription inhibitor | ChIP-Seq
Several chemotherapeutics, including the anthracyclines andcisplatin, exert part of their cytotoxicity through the in-
hibition of transcription (1). Transformed cells often require
constant expression of antiapoptotic genes for survival, making
transcription inhibition a relevant therapeutic strategy in oncol-
ogy (1, 2). Many radio- and chemotherapy treatments that target
DNA, including UV irradiation, cisplatin, and the topoisomerase
inhibitors, introduce obstacles to RNA polymerase II (RNAP2)
elongation by generating bulky or helix-distorting lesions (3–5).
In cell culture experiments, transcription blockade has been
shown to induce degradation of the RNAP2 large subunit
(RPB1), and function as a signal for p53-mediated apoptosis (6,
7). Although many DNA-targeted therapeutics effectively inhibit
transcription and induce apoptosis, clinical treatment with gen-
otoxic agents can also damage DNA in normal cells, increasing
symptomatic toxicity and potentially leading to secondary can-
cers (8). The question arises whether high-afﬁnity, noncovalent
DNA-binding ligands offer an approach to transcription in-
hibition without DNA damage.
Hairpin pyrrole-imidazole (Py-Im) polyamides are synthetic
oligomers with programmable sequence recognition that bind
the minor groove of DNA with high afﬁnity (9). Py-Im poly-
amide-DNA binding induces allosteric changes in the DNA helix
that can interfere with protein–DNA interactions (10, 11). Py-Im
polyamides have been used as molecular probes in cell culture to
modulate inducible gene-expression pathways (12–15). In
rodents, eight-ring hairpin Py-Im polyamides circulate in blood
for several hours after administration and affect changes in gene
expression in tissues (16–18).
We have previously reported that polyamide 1 (Fig. 1), which
targets the sequence 5′-WGWWCW-3′ found in the androgen
response element, inhibited a subset of dihydrotestosterone
(DHT)-induced genes in LNCaP cells (12). In this article we
explore the effects of this polyamide on the RNAP2 transcription
machinery. We ﬁnd that RNAP2 is preferentially reduced from
transcription start sites genome-wide without signiﬁcant pertur-
bation at enhancer loci. This reduction is accompanied by pro-
teasome-dependent degradation of RPB1. Polyamide treatment
induces p53 accumulation that is consistent with what is observed
for other transcription inhibitors that interact with DNA (4, 5), but
without evidence of DNA damage. This polyamide demonstrates
efﬁcacy in vivo against prostate cancer xenografts in mice with
limited host toxicity.
Results
Effects of Polyamide 1 on Global Occupancy of RNAP2. Polyamide 1
was previously shown to inhibit the induction of a subset of
DHT-driven genes in LNCaP cell culture (12). We interrogated
the effects of 1 on the RNAP2 transcription machinery by
mapping the global occupancy of RNAP2 using ChIP-seq. Under
DHT induction, select androgen receptor (AR)-driven genes,
such as KLK3, showed increased RNAP2 occupancy over genic
regions, but this was decreased in the presence of 1 (Fig. 2A).
Although RNAP2 occupancy across constitutively expressed
genes, such as GAPDH, did not change with DHT induction,
cotreatment with 1 reduced RNAP2 occupancy across these
genes (Fig. 2B). This reduction in RNAP2 occupancy by 1 was in
the context of a global decrease of RNAP2 occupancy across
genic regions (Fig. S1), particularly at transcription start sites
(Fig. 2C). However, 1 did not signiﬁcantly change RNAP2 oc-
cupancy at enhancer loci (Fig. 2D), suggesting 1 may affect the
active elongation of RNAP2 without disturbing the transcription
apparatus anchored at enhancers, and that the observed differ-
ences in RNAP2 occupancy are not a result of technical variation
in ChIP success between experiments. Reduction in DNA oc-
cupancy of RNAP2 has also been reported in cells treated with
α-amanitin, a cyclic octapeptide inhibitor of RPB1 (19).
Inhibition of RNAP2 elongation can be caused by a multitude
of genotoxic agents and often results in the degradation of the
RPB1 subunit (3, 20, 21). Indeed, in addition to reduced RNAP2
DNA occupancy, immunoblot analysis of LNCaP cells treated
with 1 shows depletion of RPB1 in a time- and concentration-
dependent manner (Fig. 2E). To examine if the effect on RPB1
protein were a result of decreased transcription of this gene, we
measured levels of RPB1 mRNA (Fig. 2F). The expression of
RPB1 modestly increased with polyamide treatment, suggesting
this depletion is posttranscriptional.
Polyamide Cytotoxicity Is Reduced by Proteasomal Inhibition and
Serum Starvation. Inhibition of RNAP2 has been reported to in-
duce apoptosis (4, 6, 22), and may contribute to polyamide cy-
totoxicity observed in LNCaP cells cultured with 1 (Fig. 3A). A
previous study with trabectidin, a DNA minor groove alkylator
that causes RPB1 degradation, showed the toxicity induced by
the molecule can be reduced by cotreatment with the protea-
some inhibitor MG132 (22). To evaluate if polyamide-induced
toxicity was also reducible by proteasomal inhibition we treated
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LNCaP cells with 2 in the presence and absence of MG132. We
developed analog 2 speciﬁcally for this application because
prolonged incubation with MG132 alone is cytotoxic, and con-
jugation of an aryl group to the γ-aminobutyric acid turn have
been shown to improve cellular uptake and cytotoxicity of pol-
yamides. Cell-viability experiments showed that 2 induced cell
death more rapidly than 1 without signiﬁcant change to DNA
binding (Fig. S2 A and B). Cell culture experiments revealed
coincubation with MG132 reduced cytotoxicity induced by 2
(Fig. 3B) and prevented degradation of RPB1 (Fig. 3C). Poly-
amide nuclear uptake was not affected by MG132 (Fig. S2 C and
D). In addition, cytotoxicity studies of cells treated with UV
radiation and α-amanitin have shown increased cellular sensi-
tivity to transcription inhibition upon S-phase entry (6, 23).
Similarly, 2 was less toxic to LNCaP cells arrested in G1/G0 by
serum starvation compared with cells grown in normal media
(Fig. 3D and Fig. S2E).
Accumulation of p53 and Expression of p53 Targets in the Absence of
DNA Damage. Previously published microarray data of LNCaP
cells cotreated with DHT and 1 revealed the induction of several
p53 target genes (12). Despite depletion of RPB1, treatment of
LNCaP cells with 1 alone induced expression of p53 genes that
are characteristic of genotoxic stress (Fig. 4A) (24). Many of
these genes were previously observed to be induced in A549 cells
treated with polyamide as well as polyamide-alkylator conjugates
(14, 25). To examine if direct DNA damage was contributing to
p53 activity, we looked for evidence of DNA damage in LNCaP
cells after extended treatment with 1. Alkaline comet assay
showed no evidence of DNA fragmentation (Fig. 4B). Addi-
tionally, treatment with 1 did not induce cellular markers of
DNA damage, including phosphorylation of γH2A.X, ATM,
DNA-PKcs, p53, or Chk2 (Fig. 4C). However, modest accu-
mulation of p53 and poly(ADP-ribose) polymerase (PARP)
cleavage were observed. These data suggest that 1 activates
p53 through transcriptional inhibition without DNA damage,
a mechanism that has been observed for non-DNA targeting
agents that exert transcriptional stress such as the protein ki-
nase inhibitor 5,6-dichlorobenzimidazole (DRB) and α-amani-
tin (5, 6, 26).
Effects of Polyamide Treatment on Prostate Cancer Xenografts. We
recently reported the toxicity and pharmacokinetic (PK) proﬁle
of 1 in mice (17). Subcutaneous injection of 1 also results in
detectable circulation (Fig. S3). We thus selected this molecule
for further testing against xenografts in vivo. Male NOD scid-γ
(NSG) mice bearing LNCaP xenografts were treated with either
vehicle or 20 nmol (∼1 mg/kg) 1 by subcutaneous injection once
every 3 d for a cycle of three injections. At the experimental end
point, mice treated with 1 had smaller tumors and lower serum
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Fig. 1. Structure of polyamides 1 and 2.
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Fig. 2. Global effects of 1 on RNAP2. Genome browser tracks of RPB1 occupancy from untreated, DHT-treated, and DHT + 1-treated samples over (A) an AR-
driven gene, KLK3 (PSA), and (B) a housekeeping gene, GAPDH. RNAP2 occupancy is mapped as reads per million. (C) Genomic RNAP2 occupancy at tran-
scription start sites show comparable levels of enrichment for nontreated and DHT treated samples. Samples treated with DHT + 1 exhibited much lower
occupancy. (D) Genomic RNAP2 occupancy at enhancer regions is largely unchanged between the three treatment conditions. (E) Immunoblot of RPB1
protein in LNCaP cells treated with 1 μM doxorubicin (dox) for 16 h, or 1 at 2 μM, 10 μM, and 20 μM for 48 and 72 h. (F) Quantitative RT-PCR measurement of
RPB1 transcript levels after LNCaP cells are treated with 10 μM 1 for the indicated times. Relative expression is normalized against nontreated cells. Data
represent mean ± SD of biological quadruplicates.
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prostate-speciﬁc antigen (PSA) compared with vehicle controls
(Fig. 5 A and B). Immunohistological analysis of selected tumors
showed evidence of cell death by TUNEL stain (Fig. 5C). Al-
though tumor-free NSG mice treated with 1 under this regimen
showed no signs of distress or weight loss, LNCaP tumor-bearing
NSG mice exhibited weight loss by the experimental end point
(Fig. S4). This weight loss was accompanied by an elevation in
serum uric acid that was not observed in either control group
(Fig. 5D).
Discussion
DNA targeting agents, including cisplatin, the anthracyclines,
minor groove binders, and UV radiation have been demon-
strated to affect a multitude of DNA-dependent enzymes, such
as the RNA polymerases, DNA polymerase, topoisomerases, and
helicases (21, 27). Our research group and others have used
polyamides as molecular tools to modulate gene-expression
programs (12–15). The programmable sequence speciﬁcity of Py-
Im polyamides offers a unique mechanism to target speciﬁc
transcription factor–DNA interfaces and thereby modulate par-
ticular gene-expression pathways. In previous studies we have
focused our analysis on speciﬁc changes to inducible pathways of
gene expression. For example, we have shown polyamide 1
affects ∼30% of the DHT-induced transcripts in LNCaP cells,
which may result from inhibition of the transcription factor AR-
DNA interface (12). However, the cellular cytotoxicity of this
polyamide may not only be a result of inhibition of DHT-induced
gene expression because analogs of 1 exhibit toxicity in a variety
of cancer cells (28). It is more likely that polyamides perturb
multiple DNA-dependent cellular processes (transcription, rep-
lication) that contribute to cytotoxicity. In this study we show
that 1 interferes with RNAP2 elongation resulting in the
degradation of RPB1, activation of p53, and triggering of apo-
ptosis, without detectable genomic damage.
Our previous study has shown polyamide 1 decreased the ex-
pression of a large number of genes in LNCaP cells (12). To
examine the effect of 1 on the transcription machinery, we per-
formed genome-wide mapping of RNAP2 occupancy by ChIP-
seq. We found that although DHT induction increased RNAP2
occupancy at select AR-driven genes, cotreatment with 1 caused
a genome-wide decrease of RNAP2 occupancy across genic
regions. The effect was most pronounced at transcription start
sites. Interestingly, RNAP2 occupancy at enhancer loci, where
the transcription assemblies may be attached via contacts
through other proteins, was not signiﬁcantly affected by poly-
amide treatment. This ﬁnding suggests polyamide 1 may pref-
erentially affect RNAP2 loading at regions where RNAP2 is
actively engaged, a mechanism that has been previously pro-
posed for the gene regulatory activity of polyamides (29).
The displacement of RNAP2 from DNA is caused by many
DNA damaging agents that pose an impediment to RNAP2
elongation. This effect is normally coupled with the degradation
of the large RNAP2 subunit RPB1. Indeed, the cellular level of
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Fig. 3. Cytotoxicity of 1 and 2 and effects on RPB1. (A) Cytotoxicity of 1 in
LNCaP cells after incubation with 1 for 72 h. Data represent mean ± SD. IC50
is calculated from three independent experiments and the error is a 95%
conﬁdence intervals. (B) Cell viability at 24 h of LNCaP cells treated with
varying concentrations 2 with and without proteasome inhibitor MG132 (3
μM, 24 h); proteasome inhibition reduces cytotoxicity of 2. (C) Immunoblot
of RPB1 protein in LNCaP cells treated with 10 μM 2 for 12 h followed by 10
μM MG132 for 4 h. (D) Cytotoxicity of 2 in LNCaP cells incubated with 10%
FBS or with 0.5% FBS for 24 h. Serum starvation decreases percent of cells in
the S phase from 8.5% to 4.4% (Fig. S2). Data represent mean ± SD.
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Fig. 4. Induction of p53 activity without evidence of DNA damage. (A) In-
duction of p53 target genes (GADD45A,MDM2, IGFBP3, P21, BAX) and DNA
damage-inducible transcript 3 (DDIT3), by 1 (10 μM) at 24, 48, and 72 h. Data
represent the mean of four biological replicates and error bars represent SD.
(B) Alkaline comet assay of LNCaP cells treated with vehicle, dox (5 μM, 4 h),
1 (10 μM, 48 h). Error bars represents maximum and minimum; boxes rep-
resents the upper and lower quartiles and median. Representative comets
for each treatment are shown. Effects of 1 are indistinguishable from the
nontreated control, but dox treatment signiﬁcantly increases comet-tail
percent of DNA. P = 0.00043. (C) DNA damage markers after treatment of
LNCaP cells with 1. There is no signiﬁcant phosphorylation of DNA-PKcs,
ATM, Chk2, p53, or γH2A.X. Accumulation p53 and PARP cleavage are ob-
served. Data are representative of biological triplicates except for DNA-PKcs,
which was in replicate.
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RPB1 in LNCaP cells was found to decrease in both a time- and
concentration-dependent manner when treated with polyamide
1. Polyamide 2, a more cytotoxic analog of 1, also reduced cel-
lular RPB1 in LNCaP cells and induced cell death. Cotreatment
of 2 with a proteasomal inhibitor MG132 was able to prevent the
degradation of RPB1 and reduce the toxicity of 2 in cell culture.
In addition, the cytotoxic effects of other RNAP2 inhibitors are
reported to be attenuated by preventing S-phase entry. LNCaP
cells arrested in G0/G1 by serum starvation also exhibited re-
duced sensitivity to 2 compared with cells grown in normal me-
dia. The ﬁnding that cytotoxicity is partially rescued by MG132
treatment and G0/G1 arrest suggests RPB1 degradation con-
tributes to cytotoxicity; however, contributions from other DNA-
dependent processes are not ruled out.
Although transcription inhibition can activate p53 signaling,
both events can be caused by DNA damage. Analysis of pre-
viously published microarray data revealed the induction of
several p53 target genes in LNCaP cells cotreated with DHT and
1 (12). Further validation of transcript levels of the genes in this
study also showed a time-dependent increase in the expression of
GADD45A, MDM2, IGFBP3, P21, BAX, and DDIT3 (Fig. 4A).
Because these genes are also markers of genotoxic stress (24)
and were found to be induced in A549 cells treated with alky-
lating polyamide derivatives (25), we searched for signs of DNA
damage to determine if it was causing transcription inhibition
and p53 activation. Interestingly, both comet assay and immun-
blot analysis of cellular DNA damage markers showed no sig-
niﬁcant signs of DNA damage. Although faint phosphorylation
of γH2A.X was visible, it is likely caused by cellular apoptosis as
indicated by the concurrent PARP cleavage. These data are
consistent with studies in yeast mutants that are hypersensitive to
DNA damage, which showed no increased sensitivity to poly-
amide treatment, suggesting these reversible DNA binders do
not compromise genomic integrity (30).
The activation of p53 by transcription inhibition in the absence
of DNA damage has been observed for DNA-independent
inhibitors of RNAP2, such as DRB, α-amanitin, and various
RNAP2-targeted antibodies (5, 6, 26). Distamycin A, the natural
product that provided the structural inspiration for Py-Im poly-
amides, inhibits the initiation of RNA synthesis in cell-free assays
(27). In cell culture, distamycin also induces degradation of
RPB1 and activates p53 (31, 32). However, low antitumor po-
tency and poor stability limit its utility.
To assess the therapeutic potential of polyamide 1 as an an-
titumor agent, LNCaP xenografts in a murine model were trea-
ted with 1 or PBS vehicle. After three rounds of treatment,
tumor growth was reduced by 64% in the treated group. Al-
though treatment with 1 alone did not cause changes in animal
body weight or obvious signs of toxicity in tumor-free animals,
treatment in tumor-bearing animals resulted in weight loss after
three treatments. The accompanied elevation in serum uric acid
may be an indication of tumor lysis syndrome (33), which is as-
sociated with rapid tumor cell turnover upon polyamide treat-
ment. We anticipate that Py-Im polyamides could also demonstrate
efﬁcacy in additional xenograft models.
Methods
Compounds and Reagents. Py-Im polyamides 1, 2, and 3 were synthesized on
oxime resin, as described previously (28, 34, 35). (R)-MG132 (MG132) was
from Santa Cruz Biotechnology.
Cell Viability Assays. LNCaP cells were plated in clear bottom 96-well plates at
5,000–7,500 cells per well. The cells were allowed to adhere for 24–36 h
before compounds were added in fresh media. Cell viability was determined
by the WST-1 assay (Roche) for 1 and 2 after 24- or 72-h incubation with cells.
Cells in cytotoxicity rescue experiments were treated with 2 alone or with 3
μM MG132 for 24 h. For cell-cycle arrest experiments, LNCaP cells were
seeded at 2,500–5,000 cells per well in normal media and allowed to adhere
for 24–36 h. The media was replaced with normal media or media supple-
mented with 0.5% (vol/vol) FBS and incubated for 48 h before treatment
with compound.
In Vivo Xenograft Experiments. All mice experiments were conducted under
an approved protocol by the Institutional Animal Care and Use Committee of
the California Institute of Technology. Male NSG mice were purchased from
The Jackson Laboratory. The animals were individually caged andmaintained
on a standard light-dark cycle. NSGmice were engrafted with LNCaP cells (2.5
million cells) in a mixture of 1:1 media and matrigel in the left ﬂank. Tumors
were grown to ∼100 mm3 (L × W2) before beginning treatment with com-
pound or vehicle. Py-Im polyamide 1 was administered once every 3 d at 20
nmol per animal (∼1 mg/kg) in a 5% (vol/vol) DMSO:PBS vehicle solution
until the experiment endpoint.
Serum Measurements. To investigate if polyamide 1 could be detected in
peripheral blood after subcutaneous injections, 120 nmol of 1 [in 5% (vol/
vol) DMSO/PBS] was injected into the right ﬂank of four C57BL/6J mice.
Blood was collected from anesthetized mice via retroorbital collection at 5
min, 4 h, and 12 h after injection, then processed by methods previously
described and analyzed by HPLC (36). For measurement of serum PSA (KLK3)
and uric acid, blood was collected from anesthetized mice via retroorbital
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collection at experimental endpoint and serum was separated from blood by
centrifugation. Serum PSA (KLK3) was measured by ELISA (R&D Systems)
according to the manufacturer’s instructions. Uric acid was measured as
previously described (37).
Chromatin Immunoprecipitation. Genomic occupancy of RNAP2 was de-
termined by ChIP with the 4H8 antibody (Abcam). LNCaP cells were plated at
35 million cells per plate in RPMI supplemented with 10% (vol/vol) CTFBS and
allowed to adhere for 24–36 h. The cells were treated with compound 1 in
fresh media (10% CTFBS) for 48 h. Cells treated and untreated with 1 were
incubated with 1 nM DHT for 6 h. Two-step cross-linking was performed as
previously described (38). After DSG removal, chromatin was immunopre-
ciated by previously published methods (39). DNA was harvested by phenol
chloroform extraction and puriﬁed with the QIAquick puriﬁcation kit (Qia-
gen). Quantitative PCR was used to validate enrichment at the GAPDH
transcription start site (Primers: F-GGTTTCTCTCCGCCCGTCTT, R-TGTTCGA-
CAGTCAGCCGCAT) compared with an internal negative locus (Primers: F-
TAGAAGGGGGATAGGGGAAC, R-CCAGAAAACTGGCTCCTTCTT). Each sam-
ple was immunoprecipated as ﬁve technical replicates. The three most
consistent samples were combined and submitted for sequencing on an
Illumina genome analyzer. Biological replicates were acquired.
Data Processing and Analysis. Sequencing reads were trimmed down to 36 bp
and then mapped against the male set of human chromosomes (excluding all
random chromosomes and haplotypes) using the hg19 version of the human
genome as a reference. Bowtie 0.12.7 was used for aligning reads (40), with
the following settings: “-v 2 -t–best–strata”. Signal proﬁles over genomic
locations were generated using custom written python scripts; the refSeq
annotation was used for gene coordinates. Enhancers and promoters were
deﬁned using previously published histone marker data (41). ChIP-seq peaks
were called using MACS2 with default settings (42). Enhancers were deﬁned
as H3K4me1+ regions that did not intersect with H3K4me3+ regions and
promoters as H3K4me3+ regions that did not intersect with H3K4me1+
regions. Clustering was performed with Cluster 3.0 (43) and visualized with
Java TreeView (44).
Comet Assay. LNCaP cells were plated at 1 million cells per 10-cm plate and
allowed to adhere for 24–36 h. Cells were then incubated with either 10 μM 1
for 48 h or 5 μM doxorubicin for 4 h. DNA damage was assayed using the
Trevigen CometAssay system and samples were prepared from harvested
cells according to the manufacture protocol. Comets were imaged on
a confocal microscope (Exciter, Zeiss) at 10× magniﬁcation. Percentage of
DNA in the tail was determined using Comet Assay Lite IV (Perceptive
Instruments). More than 100 comets were scored for each condition.
Immunoblot Assay. Samples for immunoblot analysis were prepared by
plating LNCaP or DU145 cells at 1 million cells per 10-cm plate. Cells were
allowed to adhere for 24–36 h before incubation with compound. After the
appropriate incubation time, cells were washed once with ice-cold PBS and
harvested in ice-cold 125 μL lysis buffer (50 mM Tris•HCl pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% Triton X 100) containing protease inhibitor mixture
(Roche), 1 mM PMSF (Sigma), and phosphatase inhibitors (Sigma). Samples
were incubated on ice for 10 min with vortexing once every 3 min. Cellular
debris was pelleted by spinning at 21,000 × g for 15 min to collect the su-
pernatant. Samples were then quantiﬁed for protein content with the
Bradford assay (Bio-Rad) and boiled with 4× sample buffer (Li-Cor) for 5 min.
Protein electrophoresis was performed in 4–20% precast Tris•glycine SDS
gels (Bio-Rad) and transferred to PVDF membranes. Membrane blocking was
done with Odyssey Blocking Buffer (Li-Cor). The following antibodies used to
probe changes in protein levels or phosphorylation states: RBP1 (Santa Cruz
Biotechnology; N20), p53 (Santa Cruz Biotechnology; DO1), phospho-Chk2-
Thr68 (Cell Signaling Technology), Phospho-p53-Ser15 (Cell Signaling Tech-
nology), phospho-H2A.X-Ser139 (Cell Signaling Technology), phosphor-
ATM-Ser1981 (Abcam), phospho-DNA-PKcs-Ser2056 (Abcam), and β-actin
(Abcam). Near-IR secondary antibodies (Li-Cor) were used for imaging.
Experiments were performed in biological triplicate except for DNA-
PKcs (replicate).
Flow Cytometry. To determine cell cycle distribution of LNCaP cells grown in
normal media or under serum-starved conditions, 1 million cells were seeded
to each 10-cm plate and allowed to adhere for 24–36 h. Media was then
replaced with fresh normal media [10% (vol/vol) FBS] or serum-starved
media [0.5% (vol/vol) FBS] and incubated for an additional 48 h. Cells were
then trypsinized and prepared for analysis as previously described (45).
Samples were analyzed in biological triplicate on a FACSCalibur (Becton-
Dickinson) instrument. Data analysis was performed using FlowJo 7.6.5.
Quantitative RT-PCR. RNA was extracted using RNEasy columns (Qiagen)
according to the manufacturer’s protocols. cDNA was generated from RNA
by reverse transcriptase (Transcriptor First Strand cDNA kit; Roche). Quan-
titative real-time RT-PCR was performed using SYBR Green PCR Master Mix
(Applied Biosystems) on an ABI 7300 instrument. mRNA was measured rel-
ative to β-glucuronidase as an endogenous control. Experiments were per-
formed in biological quadruplicates. For primer sequences see Table S1.
Confocal Microscopy. Cells were plated in 35-mm optical dishes (MatTek) and
dosed with polyamide 3 at 2 μM for 24 h with or without 3μM MG132. Cells
were then washed with PBS and imaged on a confocal microscope (Exciter;
Zeiss) using a 63× oil immersion lens. Confocal imaging was performed
following established protocols (34).
Histology and Immunohistochemistry. Tumors were resected immediately
after euthanasia and ﬁxed in neutral buffered formalin. Selected samples
were embedded in parafﬁn, sectioned and stained with H&E. Selected sec-
tions were assessed by TUNEL, as previously described (46).
Thermal Denaturation Assays. Polyamides 1 and 2 were incubated with du-
plex DNA 5′-CGATGTTCAAGC-3′, which contains the predicted target site for
these compounds (underlined). Melting temperature analyses were per-
formed on a Varian Cary 100 spectrophotometer as described (47). Melting
temperatures were deﬁned as a maximum of the ﬁrst derivative of absor-
bance at 260 nm over the range of temperatures.
Statistical Analysis. Statistical signiﬁcance was calculated using the Student t
test with two tailed variance. Results were considered signiﬁcant when
P < 0.05.
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